- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | Vor Biopharma: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 18.12.25 | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | 4 | Investing.com Deutsch | ||
| 17.12.25 | Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential | 1 | Investing.com | ||
| 15.12.25 | Vor Bio raises $150 million in private placement to fund clinical trials | 1 | Investing.com | ||
| 15.12.25 | Vor Bio announces $150M private placement | 5 | Seeking Alpha | ||
| 15.12.25 | Vor Biopharma: Vor Bio Announces $150 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 09.12.25 | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential | 17 | Investing.com | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target | 6 | Investing.com | ||
| 13.11.25 | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 354 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| 12.11.25 | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.11.25 | Vor Biopharma Stock Sinks 48% | 9 | RTTNews | ||
| 11.11.25 | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11.25 | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11.25 | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11.25 | Vor Bio prices $100 million public offering of common stock | 6 | Investing.com | ||
| 11.11.25 | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 241 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen | |
| 10.11.25 | Vor Bio launches $100 million common stock offering | 1 | Investing.com | ||
| 10.11.25 | Vor Bio launches $100M public stock offering | 2 | Seeking Alpha |
1 2 3 4 5 Weiter >>
82 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 1,711 | -2,40 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,006 | -1,54 % | SOL Global Investments Corp.: SOL Global Announces Share Consolidation | Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors... ► Artikel lesen | |
| TRINITY BIOTECH | 0,791 | 0,00 % | Trinity Biotech plc: Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives | - Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,910 | +3,65 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,130 | -0,97 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,460 | +2,82 % | Ovid Therapeutics is a buy, this analyst says | ||
| EQUILLIUM | 1,200 | -6,69 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| GENERATION BIO | 5,690 | +1,79 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 21,000 | -8,30 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| 4D MOLECULAR THERAPEUTICS | 7,500 | 0,00 % | Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely | ||
| CABALETTA BIO | 2,190 | +1,86 % | Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update | Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient... ► Artikel lesen | |
| LONGEVERON | 0,506 | +0,58 % | Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 | ||
| PROKIDNEY | 2,230 | 0,00 % | ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright | ||
| ATHIRA PHARMA | 7,570 | +7,83 % | Athira Pharma: Aktie knallt +170% nach NBC-Einstieg | Vorweihnachtliche Bescherung im No Brainer Club - und das am Fließband: Während Mitglieder noch mit dem Feiern der +167%-Rakete VYNE Therapeutics beschäftigt waren, schlug auch schon der nächste Volltreffer... ► Artikel lesen | |
| BOLT PROJECTS | 0,785 | -5,97 % | Bolt Projects Holdings, Inc. - 8-K, Current Report |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 13,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.